Chile - español - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - araneus diadematus d6;calcium phosphoricum d12;equisetum hiemale d4;ferrum iodatum d12;fumaria officinalis d4;gentiana lutea d5;geranium robertianum d4;juglans regia ssp. regia d3;levothyroxinum d12;myosotis arvensis d3;nasturtium officinale d4;natrium sulfuricum d4;pinus sylvestris d4;scrophularia nodosa d3;smilax d6;teucrium scorodonia d3;veronica officinalis d3 - araneus diadematus d6 15,0 mg; calcium phosphoricum d12 15,0 mg; equisetum hyemale d4 15,0 mg; ferrum iodatum d12 30,0 mg; fumaria officinalis d4 15,0 mg; gentiana lutea d5 15,0 mg; geranium robertianum d4 30,0 mg; juglans regia d3 15,0 mg; levothyroxinum d12 15,0 mg; myosotis arvensis d3 15,0 mg; nasturtium officinale d4 30,0 mg; natrium sulphuricum d4 15,0 mg; pinus sylvestris d4 15,0 mg; scrophularia nodosa d3 15,0 mg; smilax d6 15,0 mg; teucrium scorodonia d3 15,0 mg; veronica officinalis d3 15,0 mg - medicamento homeopático usado como coadyuvante en el tratamiento de apoyo al sistema linfático en infecciones asociadas con ganglios linfáticos agrandados y como terapia de apoyo para la retención leve de líquidos acompañada de hinchazón de las extremidades

España - español - Adama

adama - suspensión concentrada (sc) -  diflufenican 2,5% + clortoluron 40%  - control de malas hierbas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - aranea d6 0.55 mg; calcium phosphoricum d12 0.55 mg; equisetum hyemale d4 0.55 mg; ferrum jodatum d12 1.1 mg; fumaria officinalis d4 0.55 mg; gentiana lutea d5 0.55 mg; geranium robertianum d4 1.1 mg; levothyroxinum d12 0.55 mg; myosotis arvensis d3 0.55 mg; nasturtium officinale d4 1.1 mg; natrium sulphuricum d4 0.55 mg; pinus sylvestris d4 0.55 mg; scrophularia nodosa d3 0.55 mg; smilax d6 0.55 mg; teucrium scorodonia d3 0.55 mg; veronica officinalis d3 0.55 mg - medicamento homeopático útil como regulador linfático

Chile - español - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - araneus diadematus d6 5 g/100 g; calcium phosphoricum d12 5 g/100 g; equisetum hyemale d4 5 g/100 g; ferrum jodatum d12 10 g/100 g; fumaria officinalis d4 5 g/100 g; gentiana lutea d5 5 g/100 g; geranium robertianum d4 10 g/100 g; levothyroxinum d12 5 g/100 g; myosotis arvensis d3 5 g/100 g; nasturtium officinale d4 10 g/100 g; natrium sulphuricum d4 5 g/100 g; pinus sylvestris d4 5 g/100 g; scrophularia nodosa d3 5 g/100 g; smilax d6 5 g/100 g; teucrium scorodonia d3 5 g/100 g; veronica officinalis d3 5 g/100 g - regulador linfatico

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bayer ag -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - fenilbutazona - solución inyectable - fenilbutazona 20 g;excipientes c.s.p , fenilbutazona 20 g; excipientes c.s.p - antiinflamatorios: no esteroidales sistémicos. - camelidos, caninos, caprinos, equinos, felinos, ovinos, porcinos, vacunos - indicado principalmente en casos de artritis, bursitis, miositis, tendinitis, tendovaginitis, neuritis, impotencia coeundi del toro y del verraco. neumonía enzoótica, mastitis, enfermedades febriles agudas, entre otras.

Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unión Europea - español - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - fracturas tibiales - los medicamentos para el tratamiento de enfermedades de los huesos, las proteínas morfogenéticas de hueso - tratamiento de no sindical de tibia de por lo menos 9 meses de duración, secundario a trauma, en pacientes esqueléticamente maduros, en casos donde ha fracasado el tratamiento anterior con autoinjerto o el uso de autoinjerto es inviable.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

dopharma research b.v. - fenilbutazona - polvo oral - fenilbutazona 200 - fenilbutazona - caballos

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

chanelle pharmaceuticals manufacturing limited - fenilbutazona - polvo oral - fenilbutazona 1 - fenilbutazona - caballos no destinados a consumo humano